Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07326553 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

A Phase 4 study of Diabete Mellitus and Foot Ulcer Chronic, sponsored by BioXTek.

Recruiting
Registry status
Phase 4
Development phase
30
Enrollment target
2
Study locations

NCT07326553: Recruiting Phase 4 study of Diabete Mellitus and Foot Ulcer Chronic, sponsored by BioXTek.

NCT07326553 is a Phase 4 study of Diabete Mellitus and Foot Ulcer Chronic that is actively recruiting participants, run by BioXTek. The registered enrollment target is 30 participants, below the 203-participant average among 6 other Diabete Mellitus trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07326553, a Phase 4 study of Diabete Mellitus and Foot Ulcer Chronic, is actively recruiting participants, sponsored by BioXTek.

RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

Evaluation of Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

Primary Outcome

Proportion of subjects achieving ≥90% wound closure.

Interventions

  • BIOLOGICAL Placental Membrane

Study Locations (2)

Arizona

  • Axsendo - Phoenix

Texas

  • Axsendo Clinical Research - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-12-01
Est. Completion 2026-12-31
Phase Phase 4
BioXTek

1 total trials

What NCT07326553 shows while recruiting

NCT07326553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 203-participant average among 6 other Diabete Mellitus trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Diabete Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Placental Membrane is the first listed.

NCT07326553 reports a single indexed study location in Arizona, Texas.

Frequently Asked Questions

What is clinical trial NCT07326553 about?

NCT07326553 is a clinical study titled "Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing". Evaluation of Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

What is the current status of trial NCT07326553?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-12-01. Estimated completion is 2026-12-31.

What conditions does trial NCT07326553 study?

This clinical trial studies the following conditions: Diabete Mellitus, Foot Ulcer Chronic.

What interventions are being tested in trial NCT07326553?

The interventions under investigation include: Placental Membrane (BIOLOGICAL).

Who is sponsoring clinical trial NCT07326553?

This trial is sponsored by BioXTek, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07326553 being conducted?

This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabete Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07326553, the US trial registry maintained by the National Library of Medicine. NCT07326553 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.